Clinical Performance Evaluation of Continuous Glucose Monitoring Systems : A Scoping Review and Recommendations for Reporting
The use of different approaches for design and results presentation of studies for the clinical performance evaluation of continuous glucose monitoring (CGM) systems has long been recognized as a major challenge in comparing their results. However, a comprehensive characterization of the variability in study designs is currently unavailable. This article presents a scoping review of clinical CGM performance evaluations published between 2002 and 2022. Specifically, this review quantifies the prevalence of numerous options associated with various aspects of study design, including subject population, comparator (reference) method selection, testing procedures, and statistical accuracy evaluation. We found that there is a large variability in nearly all of those aspects and, in particular, in the characteristics of the comparator measurements. Furthermore, these characteristics as well as other crucial aspects of study design are often not reported in sufficient detail to allow an informed interpretation of study results. We therefore provide recommendations for reporting the general study design, CGM system use, comparator measurement approach, testing procedures, and data analysis/statistical performance evaluation. Additionally, this review aims to serve as a foundation for the development of a standardized CGM performance evaluation procedure, thereby supporting the goals and objectives of the Working Group on CGM established by the Scientific Division of the International Federation of Clinical Chemistry and Laboratory Medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of diabetes science and technology - 17(2023), 6 vom: 20. Nov., Seite 1506-1526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freckmann, Guido [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Accuracy |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 22.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/19322968231190941 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36098102X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36098102X | ||
| 003 | DE-627 | ||
| 005 | 20231226084159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/19322968231190941 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM36098102X | ||
| 035 | |a (NLM)37599389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freckmann, Guido |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Performance Evaluation of Continuous Glucose Monitoring Systems |b A Scoping Review and Recommendations for Reporting |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The use of different approaches for design and results presentation of studies for the clinical performance evaluation of continuous glucose monitoring (CGM) systems has long been recognized as a major challenge in comparing their results. However, a comprehensive characterization of the variability in study designs is currently unavailable. This article presents a scoping review of clinical CGM performance evaluations published between 2002 and 2022. Specifically, this review quantifies the prevalence of numerous options associated with various aspects of study design, including subject population, comparator (reference) method selection, testing procedures, and statistical accuracy evaluation. We found that there is a large variability in nearly all of those aspects and, in particular, in the characteristics of the comparator measurements. Furthermore, these characteristics as well as other crucial aspects of study design are often not reported in sufficient detail to allow an informed interpretation of study results. We therefore provide recommendations for reporting the general study design, CGM system use, comparator measurement approach, testing procedures, and data analysis/statistical performance evaluation. Additionally, this review aims to serve as a foundation for the development of a standardized CGM performance evaluation procedure, thereby supporting the goals and objectives of the Working Group on CGM established by the Scientific Division of the International Federation of Clinical Chemistry and Laboratory Medicine | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a accuracy | |
| 650 | 4 | |a clinical performance evaluation | |
| 650 | 4 | |a continuous glucose monitoring | |
| 650 | 4 | |a study design | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Eichenlaub, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Waldenmaier, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Pleus, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Wehrstedt, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Haug, Cornelia |e verfasserin |4 aut | |
| 700 | 1 | |a Witthauer, Lilian |e verfasserin |4 aut | |
| 700 | 1 | |a Jendle, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Hinzmann, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson Boija, Elisabet |e verfasserin |4 aut | |
| 700 | 1 | |a Makris, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Diem, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Nam |e verfasserin |4 aut | |
| 700 | 1 | |a Klonoff, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Nichols, James H |e verfasserin |4 aut | |
| 700 | 1 | |a Slingerland, Robbert J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes science and technology |d 2007 |g 17(2023), 6 vom: 20. Nov., Seite 1506-1526 |w (DE-627)NLM179163914 |x 1932-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:6 |g day:20 |g month:11 |g pages:1506-1526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/19322968231190941 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 6 |b 20 |c 11 |h 1506-1526 | ||